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the trigeminovascular nocisensor complex
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Abstract
Background: In the dura mater encephali a significant population of trigeminal afferents coexpress the nociceptive
ion channel transient receptor potential vanilloid type 1 (TRPV1) receptor and calcitonin gene-related peptide
(CGRP). Release of CGRP serves the central transmission of sensory information, initiates local tissue reactions and
may also sensitize the nociceptive pathway. To reveal the possible activation of meningeal TRPV1 receptors by
endogenously synthetized agonists, the effects of arachidonylethanolamide (anandamide) and N-arachidonoyl-
dopamine (NADA) were studied on dural vascular reactions and meningeal CGRP release.
Methods: Changes in meningeal blood flow were measured with laser Doppler flowmetry in a rat open cranial
window preparation following local dural applications of anandamide and NADA. The release of CGRP evoked by
endovanilloids was measured with ELISA in an in vitro dura mater preparation.
Results: Topical application of NADA induced a significant dose-dependent increase in meningeal blood flow that was
markedly inhibited by pretreatments with the TRPV1 antagonist capsazepine, the CGRP antagonist CGRP8–37, or by
prior systemic capsaicin desensitization. Administration of anandamide resulted in minor increases in meningeal blood
flow that was turned into vasoconstriction at the higher concentration. In the in vitro dura mater preparation NADA
evoked a significant increase in CGRP release. Cannabinoid CB1 receptors of CGRP releasing nerve fibers seem to
counteract the TRPV1 agonistic effect of anandamide in a dose-dependent fashion, a result which is confirmed by the
facilitating effect of CB1 receptor inhibition on CGRP release and its reversing effect on the blood flow.
Conclusions: The present findings demonstrate that endovanilloids are potential activators of meningeal TRPV1
receptors and, consequently the trigeminovascular nocisensor complex that may play a significant role in the
pathophysiology of headaches. The results also suggest that prejunctional CB1 receptors may modulate meningeal
vascular responses.
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Background
The pathophysiology of primary headaches is thought to
involve an activation of trigeminal sensory nerves that
densely innervate the dura mater encephali. The activa-
tion of trigeminal peptidergic dural afferents elicits both
nociceptive and local vascular responses. Prolonged acti-
vation of meningeal primary afferents may even sensitize
second order neurons of the nociceptive pathway in the
caudal trigeminal nucleus [1, 2]. Neurogenic inflamma-
tion of meningeal tissues is a process that accompanies
nociception and the generation of pain and is therefore
frequently used as a readout of nociceptive events pos-
sibly leading to headaches [3]. A great body of experi-
mental evidence indicates that in a variety of organs
neurogenic inflammatory responses are mediated by
chemosensitive primary sensory neurons which can be
selectively activated with capsaicin. Importantly, chemo-
sensitive afferents besides conveying nociceptive infor-
mation to the central nervous system release vasoactive
peptides, such as calcitonin gene-related peptide (CGRP)
and substance P (SP) from their peripheral endings pro-
ducing a sterile neurogenic inflammation [4–8]. Recent
studies in our laboratory have revealed that a significant
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population of meningeal sensory nerves is sensitive to
capsaicin and expresses the transient receptor potential
vanilloid type 1 (TRPV1) receptor [9–11], a non-
selective cation channel that serves as a molecular inte-
grator of different noxious stimuli, such as heat, low pH
and chemical irritants like capsaicin [12, 13]. Accord-
ingly, stimulation of dural sensory nerves with capsaicin
results in an increase in meningeal blood flow which is
mediated by CGRP via the activation of the TRPV1
receptor [9, 14]. In the meninges, the release of neuro-
peptides may be accompanied by an increase in vascular
permeability and degranulation of mast cells besides ar-
terial vasodilatation [15].
Based on experimental and clinical observations a
pathophysiological role for meningeal TRPV1 activation
in primary headaches and the TRPV1 receptor as a novel
target for antimigraine drugs have been suggested.
Hence, the specific antimigraine drug sumatriptan has
been shown to inhibit the TRPV1-mediated activation of
trigeminal ganglion neurons innervating the rat dura
mater [16]. The use of kinase inhibitors counteracting
an enhanced activity or an increased expression of the
TRPV1 receptor was also suggested as a promising new
approach of headache therapy [17]. Desensitization of
the receptor by the TRPV1 agonist olvanil modulated
neuronal activity within the trigeminocervical complex
by acting on both vanilloid and cannabinoid receptors
[18].
Activation of meningeal chemosensitive afferents ex-
pressing TRPV1 nociceptive channels may initiate a
complex interplay among the different components of
the trigeminovascular nocisensor complex that consists
of the trigeminovascular chemosensitive primary afferent
neurons with their peripheral and central processes, the
meningeal vascular bed and dural mast cells and macro-
phages [19]. The events, which follow the activation of
dural chemosensitive nocisensors, may be regarded as
components of a positive feedback regulation, which
may augment the initial vascular and nociceptive re-
sponses. In addition, neurogenic sensory vasodilatation
may have also beneficial effects by removing tissue me-
tabolites inducing, aggravating or maintaining headache
attacks [19].
Clinical studies support the role of CGRP in the
pathophysiology of headaches; during migraine attacks
increased levels of CGRP could be measured in jugular
venous blood collected from the affected side [20]. Fur-
ther, CGRP receptor antagonists seem to be promising
new drugs in the medication of migraine attacks since
they reduce significantly the severity of headache pain
[21, 22].
The significance of chemosensitive primary sensory
neurons in headache mechanisms is further supported
by the observation that some pathophysiological events
may sensitize meningeal sensory nerves [11]. Further,
the hypothesis has also been put forward that peripheral
sensitization may be responsible for the intracranial
hypersensitivity observed in migraine and other types of
headaches when otherwise innocuous stimuli or even
pulsatile changes in meningeal blood flow or intracranial
pressure activate the trigeminal nociceptive pathway
[23]. Prolonged activation of the primary sensory neu-
rons may also alter the excitability of second-order neu-
rons in the caudal trigeminal nuclear complex leading to
the central sensitization of the nociceptive pathway
which, in turn, increases the transmission of nociceptive
information [24].
Different metabolites of membrane lipids have been
recently characterized as endogenous activators of the
TRPV1 receptor [25]. Many endovanilloids were shown
to act also as endogenous cannabinoids [26]. Arachido-
nylethanolamide (anandamide) is probably the most
widely studied endogenous ligand in the trigeminal sys-
tem that acts on both cannabinoid (CB) and TRPV1 re-
ceptors. During migraine attacks endogenous ligands of
the TRPV1 receptor may play more important role in
the activation of peptidergic nociceptive primary affer-
ents than heat or low pH. Putative endovanilloids may
mediate meningeal vascular reactions in a similar way as
capsaicin, through the release of CGRP induced via the
activation of the TRPV1 receptor. In studying the bio-
logical activity of endovanilloid compounds, simultan-
eous activations of the TRPV1 and the CB receptors
with pre- and postsynaptic localizations should be con-
sidered. In the trigeminal system cannabinoid CB1 re-
ceptor immunoreactive neurons were found mainly in
the maxillary and mandibular divisions of the trigeminal
nerve [27]. These branches of the trigeminal nerve in-
nervate the temporal part of the dura mater where its
main arterial blood vessels, the branches of the middle
meningeal artery are also localized. Earlier observations
indicate, that activation of trigeminal CB1 receptors
inhibited dural vasodilatation brought about by electrical
stimulation of the dura mater [28], and the release of
CGRP induced by thermal stimulation in an in vitro
dura mater preparation [29].
The aim of this study was to reveal the contribution of
intracranial TRPV1 and CB1 receptor activation to
changes in meningeal blood flow elicited by topically ap-
plied endogenous vanilloid/cannabinoid compounds,
anandamide and N-arachidonoyl-dopamine (NADA),
which have been previously identified in dorsal root gan-
glion neurons [30–33].
Methods
Experimental animals and surgery
Experiments were approved by the Ethical Committee
for Animal Care of the University of Szeged (XIV/
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00065/2011). Study procedures were carried out in ac-
cordance with the Directive 2010/63/EU of the European
Parliament. All efforts were made to minimize the num-
ber of animals used and their suffering. Control and
capsaicin-desensitized adult male Wistar rats weighing
300–350 g were used, the number of animals in different
experimental groups were between n: 6–13. Animals
were raised and maintained under standard laboratory
conditions. Capsaicin desensitization of animals was in-
duced by subcutaneous injections of capsaicin on three
consecutive days at increasing doses of 10, 20 and
100 mg/kg [34]. Intact animals and rats given the solvent
for capsaicin (6 % ethanol and 8 % Tween 80 in saline)
served as controls. Rats were anaesthetized with an ini-
tial dose of thiopental sodium (120 mg/kg, i.p. Thiopen-
tal, Biochemie GmbH, Austria). Additional doses of
thiopental sodium (25 mg/kg i.p.) were administered
throughout the experiment to avoid changes of systemic
blood pressure or nociceptive reactions to noxious stim-
uli. Systemic blood pressure was recorded with a pres-
sure transducer via a cannula inserted into the femoral
artery. The animals were tracheotomized and breathed
spontaneously [9]. The body temperature was kept at
37–37.5 °C with a heating pad. A cranial window for the
measurement of dural blood flow was prepared accord-
ing to Kurosawa et al. [35]; the head of the animal was
fixed in a stereotaxic frame, the scalp was removed and
the parietal bone was exposed on one side. A cranial
window was drilled with a saline-cooled drill into the ex-
posed parietal bone.
Drug application
The open cranial window was filled with a modified syn-
thetic interstitial fluid (SIF) containing (in mM) 135 NaCl,
5 KCl, 1 MgCl2, 5 CaCl2, 10 glucose and 10 Hepes [36].
Stock solutions of capsaicin, capsazepine, anandamide,
NADA and the CB1 receptor antagonist AM 251 were
prepared. Capsaicin (32 mM) and capsazepine (1 mM)
were dissolved in saline containing 6 % ethanol and 8 %
Tween 80, stock solutions of anandamide (14 mM),
NADA (11 mM) and AM 251 (10 mM) were prepared
with ethanol. Before the experiment drugs were further di-
luted with SIF to their final concentration.
At the beginning of the experiments the blood flow in-
creasing effect of capsaicin (100 nM) was measured,
then anandamide or NADA were applied at increasing
concentrations (anandamide 100 nM, 1 μM and 10 μM,
NADA 10 nM, 100 nM and 1 μM). To minimize the de-
sensitizing effect of repeated vanilloid applications, in
this series of experiments drugs were applied for 3 min.
To determine the contribution of TRPV1-receptors
and the role of CGRP in the endovanilloid-induced
changes in meningeal blood flow, the TRPV1-receptor
antagonist capsazepine (10 μM) or the CGRP-receptor
antagonist CGRP8–37 (100 μM) were applied onto the
exposed surface of the dura mater, respectively. Five min
later, NADA (100 nM) was administered for 3 min. In
capsaicin-desensitized animals meningeal blood flow
changes induced by the topical application of capsaicin
(100 nM) and NADA (100 nM) were determined. In
control and capsaicin-desensitized animals histamine at
10 μM was applied onto the dura mater for 3 min after
completion of the measurement of the vanilloid-induced
blood flow changes. To study the role of CB1 receptor
activation on endovanilloid-induced meningeal vasodila-
tation, the effects of anandamide (10 μM) administra-
tions were tested before and after CB1 receptor
antagonist AM 251 (100 μM) application for 5 min. In
some experiments the vasodilatory effect of anandamide
(10 μM) was tested also after blocking both CB1- and
CGRP receptors with pre-treatment of the dura mater
with AM 251 (100 μM) and CGRP8–37 (100 μM).
Anandamide, NADA and AM 251 were purchased
from Tocris Bioscience (United Kingdom), all the other
drugs from Sigma-Aldrich Chemie Gmbh (Germany).
Measurement of dural blood flow and evaluation of data
Meningeal blood flow was recorded on-line with a nee-
dle type probe of a laser Doppler flowmeter (Perimed,
Sweden) over branches of the middle meningeal artery.
To minimize flow signals from the cortical blood vessels,
recording sites lying distant from the visible cortical
blood vessels were chosen. Under these circumstances,
changes in the laser Doppler signal almost exclusively
reflected the changes in meningeal blood flow [35].
Meningeal blood flow (measured in perfusion units, PU),
systemic blood pressure and body temperature were
stored and processed with the Perisoft program (Peri-
med, Sweden). The basal blood flow was the mean flow
value measured during a 5-min period prior to drug appli-
cation. The percentage changes induced in the blood flow
by topical applications of capsaicin, endovanilloids and
histamine were determined as mean flow values relative to
the basal blood flow, calculated as average for the 3 min
application periode. The effects of TRPV1-, CGRP- and
CB1-receptor antagonists on the endovanilloid-induced
blood flow changes were determined by comparing the
changes in blood flow in response to NADA before and
after the application of the respective antagonist(s).
Measurement of meningeal CGRP release in vitro
The release of CGRP from the dural afferent nerves was
measured by the method of Ebersberger et al. [37]. Con-
trol rats were deeply anaesthetized with thiopental so-
dium (150 mg/kg, i.p.) and decapitated. After removal of
the skin and muscles, the skull was divided into halves
along the midline and the cerebral hemispheres were re-
moved. The skull preparations were washed with SIF at
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room temperature for 30 min and then mounted in a
humid chamber at 37 °C. The cranial fossae were filled
with 300 μl of SIF solution. In one series of experiments
three consecutive samples of the superfusate were col-
lected at periods of 5 min by carefully removing the con-
tent of the skull halves with a pipette. The first sample
served as reference indicating the basal CGRP release in
the dura mater. The second sample was collected after
incubation in the presence of NADA at 100 nM and the
third sample after capsaicin at 100 nM. In another series
of experiments the effect of CB1 receptor antagonist
pre-treatment was studied on the anandamide-(10 μM)
induced CGRP release; in these preparations after meas-
uring the basal CGRP release, anandamide (10 μM) was
applied twice for five minutes. CB1 receptor antagonist
AM 251 was applied at 100 μM prior to the second
anandamide application. All samples were frozen at
−70 °C for later analysis.
The CGRP contents of the samples were measured by
enzyme-linked immunoassay kit (Bertin Pharma,
France). The absorbance of the reaction product repre-
senting the CGRP content of the sample was determined
photometrically, using a microplate reader (DYNEX
MRX). CGRP content was measured in pg/ml, changes
induced in CGRP release by vanilloids were expressed as
percentage changes relative to the basal release calcu-
lated for the 5-min application period. Changes in
anandamide-induced CGRP release were compared be-
fore and after blocking the CB1 receptors with its
antagonist.
Statistics
All values were expressed as mean ± SEM. Statistical
analysis of the data was performed using Statistica 12
(StatSoft, Tulsa, OK, USA). For the statistical compari-
sons one-way ANOVA followed by the Bonferroni test
was used. A probability level of p < 0.05 was regarded as
statistically significant.
Results
Effect of topical application of vanilloids on dural blood
flow
In accord with previous findings [9], in control rats topical
application of the exogenous vanilloid capsaicin at a con-
centration of 100 nM produced significant increases in
blood flow which amounted to 16.4 ± 3.4 % (n = 7, p =
0.002) of the baseline value. Administration of the endova-
nilloid anandamide resulted in minor changes of menin-
geal blood flow. At concentrations of 100 nM and 1 μM
anandamide slightly increased meningeal blood flow by
3.4 ± 1.5 (n = 8, p = 0.06) and 2.5 ± 1 % (n = 10, p = 0.033),
respectively, whereas at the highest concentration tested
in our experiments (10 μM), it had a slight vasoconstrictor
effect decreasing blood flow by 2.1 ± 0.8 % (n = 10, p =
0.022). Topical application of NADA induced a significant
dose-dependent increase in meningeal blood flow which
amounted to 7.4 ± 2 % (n = 10, p = 0.003) and 24 ± 4.7 %
(n = 11, p = 0.016) at concentrations of 10 nM and 100
nM, respectively. However, NADA applied at 1 μM de-
creased meningeal blood flow by 7.7 ± 4.3 % (n = 6, p =
0.09; Table 1). Systemic blood pressure was not influenced
by topical applications of endovanilloids or capsaicin. Sys-
tolic blood pressure measured before and after the appli-
cations of the compounds was 110 ± 22.4 and 92 ±
27.8 mmHg (p = 0.20).
Effect of systemic capsaicin desensitization on vanilloid-
induced changes in meningeal blood flow
In accord with our previous observations, in capsaicin-
desensitized animals the vasodilatory effect of capsaicin
(100 nM) was completely abolished. It was 99.8 ± 1 % of
the basal flow (n = 10, p = 0.91). Similarly, in capsaicin-
desensitized animals the administration of NADA (100
nM) resulted in a slight decrease (0.9 ± 1.2 %, n = 13, p =
0.018) in blood flow instead of the marked vasodilatory ef-
fect observed in control animals (Fig. 1). Systolic blood
pressure of capsaicin-desensitized animals was in the same
range as in controls (97 ± 17.3 mmHg) and it was not
affected by the applications of the compounds.
Desensitization with capsaicin did not interfere with local
vascular mechanisms involved in vasodilatation, since top-
ical application of histamine resulted in similar increases
of 22.3 ± 0.7 (n = 10) and 19.3 ± 0.5 % (n = 7, p = 0.64) in
meningeal blood flow in control and desensitized rats,
respectively.
Effect of capsazepine and CGRP8–37 on changes of
meningeal blood flow elicited by endovanilloids
To obtain pharmacological evidence for the involvement
of TRPV1 receptor activation and consequent CGRP re-
lease in endovanilloid-induced meningeal vasodilatation,
the specific TRPV1 receptor antagonist capsazepine
(10 μM) or the CGRP receptor antagonist CGRP8–37
(100 μM) were applied topically prior to NADA (100
nM). Administrations of capsazepine and CGRP8–37 did
Table 1 Effects of topical applications of anandamide and
NADA on meningeal blood flow
Concentration Changes in
blood flow (%)
Number p-value
Anandamide 100 nM 3.4 ± 1.5 8 0.06
1 μM 2.5 ± 1* 10 0.033
10 μM −2.1 ± 0.8* 10 0.022
NADA 10 nM 7.4 ± 2* 10 0.003
100 nM 24 ± 4.7* 11 0.016
1 μM −7.7 ± 4.3 6 0.09
*: Statistically different from the baseline (p < 0.05)
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not significantly influence basal blood flow, but resulted
in a significant inhibition of the vasodilatory effect of
NADA. Following the application of capsazepine the
blood flow increasing effect of NADA was only 2.23 ±
3.3 % (n = 8, p = 0.019), while after the application of
CGRP8–37, NADA elicited a moderate decrease in men-
ingeal blood flow by 4.82 ± 1.42 % (n = 11, p < 0.001;
Fig. 1).
Modulating effect of CB1 receptor activation on
endovanilloid-induced changes in meningeal blood flow
In control rats, dural application of a CB1 receptor
antagonist AM 251 (100 μM) did not affect basal menin-
geal blood flow. Although anandamide, at a concentra-
tion of 10 μM had a moderate vasoconstrictor effect on
meningeal blood vessels, following the administration of
AM 251 prior to the application of anandamide, a mod-
erate but significant increase in meningeal blood flow
was recorded. Indeed, the slight decrease by 2.1 ± 0.8 %
produced by anandamide (10 μM) turned into an in-
crease by 4.1 ± 0.6 % after pre-treatment with the CB1
antagonist (n = 10, p < 0.001). This vasodilatory effect of
anandamide was abolished after additional blocking of
CGRP receptors by pre-treatment with CGRP8–37
(100 μM) resulting in a decrease of blood flow by 1.1 ±
1.8 % (n = 6, p = 0.005; Fig. 2).
Effect of endovanilloids on the release of CGRP in the
in vitro dura mater preparation
The basal release of CGRP amounted to 22.6 ± 5 pg/ml
in the in vitro dura mater preparations. NADA at 100
nM induced a marked increase in the release of CGRP
amounting to 140.3 ± 16.2 % of the basal release (n = 11,
p = 0.024). In this series of experiments the capsaicin-
induced CGRP release was also measured following the
challenge with NADA in the same preparation. The
capsaicin-induced release of CGRP amounted to 328.8 ±
63.6 % of the basal value (n = 11, p = 0.008). Under these
experimental conditions, the capsaicin-induced peptide
release was taken as an indication of the functional in-
tegrity of the dura mater preparations. In the other
series of experiments, the anandamide (10 μM)-induced
release of CGRP was studied. Anandamide-induced re-
lease of CGRP amounted to 122.2 ± 9.6 % (n = 10, p =
0.08) of the basal, while after blocking the CB1 receptors
with AM 251 (100 μM) an increase of 170.4 ± 23.7 % (n
= 10) was measured. The changes in anandamide-
induced peptide release measured after blocking the
CB1 receptors were significantly different both from the
baseline release and the anandamide-induced CGRP re-
lease (SIF vs. anadamide + AM 251: p = 0.05; ananda-
mide vs. anadamide + AM 251: p = 0.04; Fig. 3).
Discussion
The present findings furnish evidence for the vascular
actions of anandamide and NADA in the dura mater
encephali and suggest that endovanilloid compounds
may bear significance in the activation of the trigeminal
nocisensor complex implicated in the pathophysiology of
headaches [3, 9, 19, 38]. The results indicate, that en-
dogenous membrane lipid metabolites which have been
already identified in primary sensory ganglion cells may
activate trigeminal chemosensitive afferent nerves which
express the TRPV1 nociceptor ion channel. Available ex-
perimental evidence indicates that activation of chemo-
sensitive primary sensory neurons plays an important
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role in the pathophysiology of certain headaches. For ex-
ample, it has been demonstrated that, in a rat experi-
mental headache model, activation of meningeal TRPV1
receptors by capsaicin resulted in the release of CGRP
from trigeminal afferent nerves. Further, release of
CGRP and expression of c-fos in the trigeminal nucleus
caudalis were significantly inhibited by TRPV1 antago-
nists [14]. The release of vasoactive neuropeptides, in
particular CGRP from both central and peripheral tri-
geminal terminals modulates the activity of second order
neurons of the trigeminal nucleus caudalis [39] and in-
creases meningeal blood flow [9, 35]. Hence, measure-
ments of the changes in dural blood flow in vivo, and
the release of CGRP from meningeal sensory nerves in
vitro, are reliable indicators of the activation of trigemi-
nal nociceptive primary sensory neurons [9, 40–42].
Endovanilloids are defined as endogenous ligands of the
TRPV1 receptor and are synthetized or may be taken up
by sensory ganglion neurons [30, 43]. Anandamide and
NADA are two membrane lipid metabolites present in
primary sensory ganglion neurons acting on both TRPV1
and CB1 receptors with different efficacies. The cellular
concentration of endovanilloids may be elevated either
by increased activity of the synthetizing enzymes and/or
by increased endovanilloid transport across the cell
membrane [44]. Several lines of evidence suggest that
anandamide binds to the same binding site of the TRPV1
receptor as capsaicin [45]. Further, anandamide may
activate the TRPV1 receptors under experimental and
pathophysiological conditions leading to sensitization of
nociceptive primary afferent neurons [46–48]. Although
tissue content of anandamide measured under physio-
logical conditions is moderate [49], its level may increase
through neurogenic inflammatory processes mediated by
meningeal peptidergic nociceptive afferents and mast
cells [19].
The present findings indicate that the vasoregulatory pro-
pensities of anandamide and NADA are different in the tri-
geminovascular system. While anandamide induced only
slight, if any, increase, NADA produced a marked increase
in meningeal blood flow. This difference may be explained
by the different activity of these agents on TRPV1 and CB1
receptors [50]. The application of endovanilloids at higher
concentrations turned the vasodilatory effects of lower
concentrations of anandamide and NADA into slight
vasoconstriction. This phenomenon is similar to the
concentration-dependent effects of the archetypal exogen-
ous vanilloid capsaicin on mesenteric, renal and meningeal
blood flow [9, 51–53]. Capsaicin-induced vasoconstriction
is generally regarded as a direct vascular action of capsaicin
[54–56], although a TRPV1 receptor mediated effect can
not be fully excluded [57]. Systemic pretreatment of the
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animals with capsaicin producing profound depletions of
sensory neuropeptides CGRP and SP from afferent nerves
markedly inhibited the vasodilatory effect of endovanilloids.
In contrast, histamine-induced vasodilatation mediated by
a direct action on endothelial and smooth muscle receptors
was not affected by capsaicin-desensitization [10, 58]. Cap-
sazepine, a specific antagonist of the TRPV1 receptors and
blockage of CGRP receptors by CGRP8–37 inhibited the
NADA-induced vasodilatation. The present findings
therefore suggest that, besides exogenous vanilloids, endo-
vanilloids can also elicit sensory neurogenic meningeal
vasodilatation involving chemosensitive afferent nerves
which express the TRPV1 receptor.
The moderate vasodilatory effect of anandamide in
our in vivo blood flow model can be explained by its
dual effects on both TRPV1 and presynaptic CB1 recep-
tors, the latter inhibiting the release of CGRP from tri-
geminal nerve fibres [59]. Immunhistochemical studies
revealed the presence of CB1 receptors on trigeminal
nerve fibres and ganglion cells [59, 60]. The relatively
strong activity of anandamide on CB1 receptors may
interfere with its endovanilloid action stimulating
TRPV1 receptors and CGRP release in the meningeal
tissue. Our notion about the interaction between TRPV1
and CB1 receptor activation in the meningeal blood flow
regulatory effect of anandamide application was sup-
ported by the observation, that blockage of CB1
receptors with AM251 has a potentiating effect on
anandamide-induced vasodilatation. This vasodilatation
was induced by the enhanced release of the sensory
vasodilator neuropeptide CGRP, since additional block-
age of CGRP receptors abolished the anandamide-
induced vasodilatation after CB1 receptor antagonism.
Although in vivo anandamide failed to significantly in-
crease meningeal blood flow, in vitro a slight but non-
significant increase in meningeal CGRP-release was
measured after the application of anandamide at the
same concentration (10 μM). The putative blood flow
increasing effect of the moderate amount of CGRP re-
leased by anandamide is probably counterbalanced by its
direct vasoconstrictor effect. Blocking the presynaptic
CB1 receptors induced a more than threefold increase in
the amount of CGRP released in the in vitro dura mater
preparation; the vasodilator effect of this higher amount
of CGRP could override the direct vasoconstrictor effect
of anandamide. After CB1 receptor blockade, the
anandamide-induced vasodilatation was mediated en-
tirely by CGRP, since it was completely abolished by pre-
treatment with the CGRP antagonist.
Conclusions
In conclusion, the present study demonstrated that simi-
lar to exogenous vanilloid compounds, endovanilloids
synthesized or taken up by sensory neurons are capable
of the activation of trigeminovascular nociceptive affer-
ent nerves resulting in the release of CGRP and a conse-
quent increase in meningeal blood flow. Chemosensitive
afferents expressing the TRPV1 receptor may contribute
significantly not only to the vascular reactions but also
to the nociceptive mechanisms of the dura mater pos-
sibly associated with the pathomechanisms of headaches.
Increased production and/or uptake of endovanilloids
may be implicated in the sustained activation of the
trigeminal sensory system leading to peripheral and/or
central sensitization of the nociceptive pathway and,
eventually head pain.
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